---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-066518"
form_type: "8-K"
ticker: "KTTA"
cik: "0001841330"
company_name: "Pasithea Therapeutics Corp."
filed_at: "2021-12-21T23:59:59+00:00"
generated_at: "2026-06-27T23:26:51.586079+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pasithea Therapeutics enters new CEO employment agreement with Tiago Reis Marques

## Summary
- Base salary $450,000; sign-on bonus $100,000 lump sum after Jan 1, 2022.
- Annual discretionary bonus up to 75% of base salary.
- Equity grants: 200,000 RSUs and 200,000 options vesting over 3 years (33% after 12 months, then quarterly).
- Severance: 12 months base salary if terminated without cause, subject to separation agreement.
- Agreement effective January 1, 2022; Board approved equity grants on Dec 20, 2021.

## SEC filing metadata
- accession: 0001213900-21-066518
- form_type: 8-K
- ticker: KTTA
- cik: 0001841330
- company_name: Pasithea Therapeutics Corp.
- filed_at: 2021-12-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841330/000121390021066518/0001213900-21-066518-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841330/000121390021066518/ea152745-8k_pasithea.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-066518
- JSON: https://secwatch.observer/filing/0001213900-21-066518.json
- Plain text: https://secwatch.observer/filing/0001213900-21-066518.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.